Aligos Therapeutics initiates dosing in healthy volunteers with siRNA drug candidate ALG-125755

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2022 — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with ALG-125755, an siRNA targeting the production of hepatitis B surface antigen (HBsAg), was initiated in healthy volunteers in Study ALG-125755-501 (NCT05561530).

“Emerging data continue to indicate that siRNA drugs targeting HBsAg production have the potential to become a cornerstone therapy to achieve functional cure in chronic hepatitis B,” said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos. “Drugs in this class have generally been well tolerated and have consistently lowered HBsAg levels with more convenient dosing frequencies compared to other injectable HBsAg lowering agents. This, coupled with the longer duration of action observed in nonclinical studies for ALG-125755 compared to other siRNAs, suggests that ALG-125755 has the potential to be administered less frequently than other drugs in this class.”

“This is an important first step in the clinical evaluation of the safety, pharmacokinetics, and antiviral activity of ALG-125755,” said Matthew W. McClure, M.D., Chief Medical Officer of Aligos. “We plan to evaluate single ascending doses across multiple cohorts of healthy volunteers in Q4 2022. Following that, beginning in Q1 2023, we then plan to evaluate single ascending doses across multiple cohorts of subjects with chronic hepatitis B. If the safety, pharmacokinetics, and pharmacodynamics of ALG-125755 in Phase 1 are favorable, we then plan to combine this drug with other mechanisms of action in Phase 2, where we hope to achieve high rates of functional cure.”

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.